2.1. Study Population
LGA, kidneys, digestive disease, gestational diabetes
GESTATIONAL HYPERTENSION, IMMUNODEFICIENCY, GESTATIONAL DIABETES, MEDICAL COMPLICATION
Between October 2019 and August 2021, healthy women who were scheduled to give birth or deliver a healthy full-term baby at Matsumoto City Hospital were recruited and subsequently provided written informed consent for participation in the study. Eligible participants were apparently healthy children born within 7 days whose gestational age at birth was ≥37 weeks and ˂42 weeks. Exclusion criteria for mothers were as follows: mothers who were diagnosed with any severe liver, renal, cardiovascular, respiratory, endocrine, metabolic, or mental disease or planned to administer any other probiotic supplements to their infants during the study period. Mothers with gestational diabetes or gestational hypertension were not excluded. Exclusion criteria for infants were as follows: infants born with multiple births and infants born with medical complications such as small for gestational age (SGA), large for gestational age (LGA), blood, liver, heart, kidneys, digestive disease, or suspected immunodeficiency or who had exposure to any oral or intravenous antibiotics or who were judged to be inappropriate to participate in the trial by the principal investigator.